This is a working overview of phase 2 trial, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-11. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
telestability The transmission of three‐dimensional structural stability from a stable part of a macromolecule to a distal part of the same molecule, especially an inherently less stable part. Instability may also be transmitted in this way, e.g. destabilization of the DNA double helix may occur at a locus that is relatively distant from the binding site of a DNA-binding protein.
In a 1951 letter to the publisher Milton Waldman (1895–1976), Tolkien wrote about his intentions to create a "body of more or less connected legend", of which "[t]he cycles should be linked to a majestic whole, and yet leave scope for other minds and hands, wielding paint and music and drama". The hands and minds of many artists have indeed been inspired by Tolkien's legends. Personally known to him were Pauline Baynes (Tolkien's favourite illustrator of The Adventures of Tom Bombadil and Farmer Giles of Ham) and Donald Swann (who set the music to The Road Goes Ever On). Queen Margrethe II of Denmark created illustrations to The Lord of the Rings in the early 1970s. She sent them to Tolkien, who was struck by the similarity they bore in style to his own drawings. Tolkien was not implacably opposed to the idea of a dramatic adaptation, however, and sold the film, stage and merchandise rights of The Hobbit and The Lord of the Rings to United Artists in 1968. United Artists never made a film, although the director John Boorman was planning a live-action film in the early 1970s. In 1976 the rights were sold to Tolkien Enterprises, a division of the Saul Zaentz Company, and the first film adaptation of The Lord of the Rings was released in 1978 as an animated rotoscoping film directed by Ralph Bakshi with screenplay by the fantasy writer Peter S. Beagle. It covered only the first half of the story of The Lord of the Rings.
=== Protein === Additional research on sponge proteins found that of 42 sponge proteins that were analysed, all of them had homologous proteins that are found in humans. An identity score of 53% was given to the similarity among sponge and human proteins, compared to a score of 42% when the same sequence was compared to that of C. elegans.
== Classification == Cerebrospinal fluid leaks are classified into two distinct disorders: cranial leaks, and spinal leaks. Where there has been no preceding surgery or medical procedure that may have caused a CSF leak it is called a spontaneous CSF leak (sCSF leak).
Sources: en.wikipedia.org
In the United States the press began using the terms "Jewish National Home", "Jewish State", "Jewish republic" and "Jewish Commonwealth" interchangeably. Treaty expert David Hunter Miller, who was at the conference and subsequently compiled a 22 volume compendium of documents, provides a report of the Intelligence Section of the American Delegation to the Paris Peace Conference of 1919 which recommended that "there be established a separate state in Palestine," and that "it will be the policy of the League of Nations to recognize Palestine as a Jewish state, as soon as it is a Jewish state in fact." The report further advised that an independent Palestinian state under a British League of Nations mandate be created. Jewish settlement would be allowed and encouraged in this state and this state's holy sites would be under the control of the League of Nations. Indeed, the Inquiry spoke positively about the possibility of a Jewish state eventually being created in Palestine if the necessary demographics for this were to exist. Historian Matthew Jacobs later wrote that the US approach was hampered by the "general absence of specialist knowledge about the region" and that "like much of the Inquiry's work on the Middle East, the reports on Palestine were deeply flawed" and "presupposed a particular outcome of the conflict". He quotes Miller, writing about one report on the history and impact of Zionism, "absolutely inadequate from any standpoint and must be regarded as nothing more than material for a future report".
Tui na (推拿) is a form of massage, based on the assumptions of TCM, from which shiatsu is thought to have evolved. Techniques employed may include thumb presses, rubbing, percussion, and assisted stretching.
Degarelix, sold under the brand name Firmagon among others, is a hormonal therapy used in the treatment of prostate cancer. Testosterone is a male hormone that promotes growth of many prostate tumours and therefore reducing circulating testosterone to very low (castration) levels is often the treatment goal in the management of advanced prostate cancer. Degarelix has an immediate onset of action, binding to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocking their interaction with GnRH. This induces a fast and profound reduction in luteinizing hormone (LH), follicle-stimulating hormone (FSH) and in turn, testosterone suppression.
O'Conner won 158,590 votes to Ayyadurai's 104,782, Ayyadurai alleged that over one million ballots had been destroyed and that the state had committed election fraud. He alleged that ballot images had to be preserved for 22 months and were now missing. However, MIT political science professor Charles Stewart stated that federal law only requires that physical ballots be stored. Harvard law professor Nicholas Stephanopoulos disputed Ayyadurai's allegation of fraud and a spokesperson for the state accused him of spreading misinformation. Fact checkers at Reuters and the Associated Press labelled the allegations as false. On February 1, 2021, Ayyadurai was suspended from Twitter. On February 3, he filed a lawsuit against Massachusetts politician William Galvin and other Massachusetts election officials, alleging that they were responsible for Twitter's suspending him. On August 10, Ayyadurai dropped the lawsuit along with an October 2020 suit against Galvin.
== See also == Chemical pneumonitis Composition of heated tobacco product emissions Adverse effects of electronic cigarettes List of additives in cigarettes List of cigarette smoke carcinogens Safety of electronic cigarettes Vaping-associated pulmonary injury
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.